|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PHF20L1 |
Gene summary for PHF20L1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PHF20L1 | Gene ID | 51105 |
| Gene name | PHD finger protein 20 like 1 | |
| Gene Alias | CGI-72 | |
| Cytomap | 8q24.22 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A0A0MQS0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51105 | PHF20L1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.15e-14 | -5.20e-01 | 0.0155 |
| 51105 | PHF20L1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.86e-04 | -4.45e-01 | -0.1808 |
| 51105 | PHF20L1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.50e-03 | -4.68e-01 | -0.1207 |
| 51105 | PHF20L1 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.04e-15 | -4.40e-01 | -0.1464 |
| 51105 | PHF20L1 | HTA11_866_2000001011 | Human | Colorectum | AD | 3.92e-11 | -4.45e-01 | -0.1001 |
| 51105 | PHF20L1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.85e-05 | -4.25e-01 | -0.059 |
| 51105 | PHF20L1 | HTA11_866_3004761011 | Human | Colorectum | AD | 5.12e-09 | -4.79e-01 | 0.096 |
| 51105 | PHF20L1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 2.26e-04 | -4.68e-01 | 0.0338 |
| 51105 | PHF20L1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.81e-10 | -4.17e-01 | 0.0674 |
| 51105 | PHF20L1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.62e-14 | -4.30e-01 | 0.294 |
| 51105 | PHF20L1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.35e-04 | -3.40e-01 | 0.3859 |
| 51105 | PHF20L1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.95e-12 | -4.42e-01 | 0.3005 |
| 51105 | PHF20L1 | A015-C-203 | Human | Colorectum | FAP | 3.27e-16 | -1.09e-01 | -0.1294 |
| 51105 | PHF20L1 | A002-C-201 | Human | Colorectum | FAP | 1.00e-03 | -8.03e-02 | 0.0324 |
| 51105 | PHF20L1 | A001-C-108 | Human | Colorectum | FAP | 5.05e-09 | 6.77e-02 | -0.0272 |
| 51105 | PHF20L1 | A002-C-205 | Human | Colorectum | FAP | 1.53e-11 | 2.49e-02 | -0.1236 |
| 51105 | PHF20L1 | A015-C-006 | Human | Colorectum | FAP | 8.66e-07 | -9.57e-02 | -0.0994 |
| 51105 | PHF20L1 | A015-C-106 | Human | Colorectum | FAP | 1.56e-05 | -3.00e-02 | -0.0511 |
| 51105 | PHF20L1 | A002-C-114 | Human | Colorectum | FAP | 4.69e-09 | 2.23e-02 | -0.1561 |
| 51105 | PHF20L1 | A015-C-104 | Human | Colorectum | FAP | 9.52e-16 | -6.86e-02 | -0.1899 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016570 | Colorectum | MSS | histone modification | 113/3467 | 463/18723 | 8.37e-04 | 8.68e-03 | 113 |
| GO:00165701 | Colorectum | FAP | histone modification | 94/2622 | 463/18723 | 1.06e-04 | 1.76e-03 | 94 |
| GO:00165702 | Colorectum | CRC | histone modification | 75/2078 | 463/18723 | 4.95e-04 | 7.06e-03 | 75 |
| GO:00182057 | Esophagus | HGIN | peptidyl-lysine modification | 88/2587 | 376/18723 | 2.99e-07 | 1.39e-05 | 88 |
| GO:00165708 | Esophagus | HGIN | histone modification | 92/2587 | 463/18723 | 1.70e-04 | 3.30e-03 | 92 |
| GO:00064735 | Esophagus | HGIN | protein acetylation | 45/2587 | 201/18723 | 6.17e-04 | 8.58e-03 | 45 |
| GO:00183945 | Esophagus | HGIN | peptidyl-lysine acetylation | 39/2587 | 169/18723 | 7.46e-04 | 9.90e-03 | 39 |
| GO:00435435 | Esophagus | HGIN | protein acylation | 51/2587 | 243/18723 | 1.33e-03 | 1.57e-02 | 51 |
| GO:00064755 | Esophagus | HGIN | internal protein amino acid acetylation | 36/2587 | 160/18723 | 1.87e-03 | 2.01e-02 | 36 |
| GO:00183935 | Esophagus | HGIN | internal peptidyl-lysine acetylation | 35/2587 | 158/18723 | 2.82e-03 | 2.75e-02 | 35 |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
| GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
| GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
| GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
| GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
| GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:00165703 | Liver | NAFLD | histone modification | 90/1882 | 463/18723 | 5.74e-10 | 1.28e-07 | 90 |
| GO:0018205 | Liver | NAFLD | peptidyl-lysine modification | 65/1882 | 376/18723 | 9.42e-06 | 3.02e-04 | 65 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PHF20L1 | SNV | Missense_Mutation | c.725N>A | p.Leu242His | p.L242H | A8MW92 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.936) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
| PHF20L1 | SNV | Missense_Mutation | c.2449N>G | p.Gln817Glu | p.Q817E | A8MW92 | protein_coding | tolerated(0.33) | benign(0) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| PHF20L1 | SNV | Missense_Mutation | novel | c.2073N>T | p.Glu691Asp | p.E691D | A8MW92 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PHF20L1 | SNV | Missense_Mutation | c.2588N>G | p.Tyr863Cys | p.Y863C | A8MW92 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PHF20L1 | SNV | Missense_Mutation | novel | c.2413N>G | p.Leu805Val | p.L805V | A8MW92 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
| PHF20L1 | SNV | Missense_Mutation | novel | c.907N>A | p.Glu303Lys | p.E303K | A8MW92 | protein_coding | deleterious(0.02) | benign(0.072) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PHF20L1 | SNV | Missense_Mutation | c.886N>A | p.Glu296Lys | p.E296K | A8MW92 | protein_coding | tolerated(0.15) | benign(0.226) | TCGA-C8-A274-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| PHF20L1 | SNV | Missense_Mutation | c.2132N>A | p.Gly711Glu | p.G711E | A8MW92 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A13Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| PHF20L1 | SNV | Missense_Mutation | c.1927N>C | p.Phe643Leu | p.F643L | A8MW92 | protein_coding | tolerated(0.09) | benign(0.223) | TCGA-EW-A2FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | goserelin | SD | |
| PHF20L1 | SNV | Missense_Mutation | novel | c.2656N>C | p.Asp886His | p.D886H | A8MW92 | protein_coding | deleterious(0.01) | possibly_damaging(0.541) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |